西妥昔单抗联合改良FOLFOXIRI一线治疗RAS/BRAF野生型转移性结直肠癌的随机II期研究
这项多中心随机II期研究纳入143例RAS/BRAF野生型初治转移性结直肠癌患者,接受mFOLFOXIRI联合西妥昔单抗诱导治疗后随机分为西妥昔单抗或贝伐珠单抗维持治疗。两臂10个月无进展生存率分别为50.8%和40.4%,均未达到主要终点,但方案可行性好且客观缓解率达71.6%。
要点
- mFOLFOXIRI联合西妥昔单抗诱导方案在RAS/BRAF野生型mCRC中可行且缓解率高。
- 西妥昔单抗维持组10个月PFS率为50.8%,贝伐珠单抗维持组为40.4%,均未达主要终点。
- 主要3/4级不良事件为中性粒细胞减少(31%)、腹泻(18%)和皮肤毒性(16%)。
核心结论
- 两臂均未达到10个月无进展生存率的主要终点,但4个月mFOLFOXIRI联合西妥昔单抗诱导方案可行且活性结果显著,手术切除率高。
研究设计与样本
- 前瞻性、非比较性、开放标签、多中心随机II期试验,2011年10月19日至2015年3月1日从意大利21个肿瘤中心招募患者,随访至2017年5月31日。
- 共筛查323例,随机143例RAS/BRAF野生型(修正前为KRAS野生型)不可切除初治mCRC患者至A臂(西妥昔单抗维持)或B臂(贝伐珠单抗维持)。
- 主要分析在改良意向治疗人群(116例)中进行,中位随访44.0个月。
主要发现
- A臂10个月无进展生存率为50.8%(90% CI 39.5%-62.2%),B臂为40.4%(90% CI 29.4%-52.1%)。
- 总体客观缓解率为71.6%(95% CI 62.4%-79.5%)。
- 主要3/4级不良事件:中性粒细胞减少36例(31%)、腹泻21例(18%)、皮肤毒性18例(16%)、乏力11例(9%)、口腔炎7例(6%)、发热性中性粒细胞减少3例(3%)。
临床怎么用
- 对于RAS/BRAF野生型mCRC,4个月mFOLFOXIRI联合西妥昔单抗诱导方案可作为强化一线治疗选择,需关注中性粒细胞减少和腹泻等毒性。
- 维持治疗阶段西妥昔单抗或贝伐珠单抗均可考虑,但西妥昔单抗维持组10个月PFS率数值上更高,需进一步验证。
局限性
- 非比较性II期设计,样本量有限(116例改良意向治疗人群),无法直接比较两维持臂的优劣。
- 主要终点未达到,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The combination of a triple-drug chemotherapy regimen with an anti-epidermal growth factor receptor (EGFR) agent as a first-line treatment of metastatic colorectal cancer (mCRC) showed promising activity along with safety concerns in single-arm phase 2 trials. The role of maintenance following chemotherapy and anti-EGFR and the optimal regimen to be adopted are not established. OBJECTIVES: To evaluate the activity and safety of cetuximab plus modified FOLFOXIRI (mFOLFOXIRI) and explore the role of maintenance with cetuximab or bevacizumab in RAS and BRAF wild-type mCRC. DESIGN, SETTING, AND PARTICIPANTS: In a prospective, noncomparative, open-label, multicenter, randomized phase 2 trial, patients aged 18 to 75 years with unresectable, previously untreated RAS and BRAF wild-type (before amendment, KRAS wild-type) mCRC were recruited from 21 oncology units in Italy from October 19, 2011, to March 1, 2015 (followed up through May 31, 2017). In total, 323 patients were screened and 143 were randomized to 2 treatment arms to receive as a first-line induction a regimen of mFOLFOXIRI plus cetuximab followed by cetuximab (arm A) or bevacizumab (arm B) until disease progression. Primary analyses were conducted in a modified intention-to-treat population. INTERVENTIONS: mFOLFOXIRI plus cetuximab repeated every 2 weeks for up to 8 cycles, followed by maintenance with cetuximab or bevacizumab until disease progression. MAIN OUTCOMES AND MEASURES: The primary end point was the 10-month progression-free rate (PFR); secondary end points included progression-free and overall survival, response rate, rate of metastases resection, and adverse events. RESULTS: Of 143 patients randomized, 116 (81.1%) (median [interquartile range (IQR)] age, 59.5 [53-67] years; 34 [29.3%] women) had RAS and BRAF wild-type mCRC. At a median (IQR) follow-up of 44.0 (30.5-52.1) months, 10-month PFRs were 50.8% (90% CI, 39.5%-62.2%) in arm A and 40.4% (90% CI, 29.4%-52.1%) in arm B. The overall response rate was 71.6% (95% CI, 62.4%-79.5%). Main grade 3/4 adverse events were neutropenia (occurring in 36 patients [31%]), diarrhea (in 21 patients [18%]), skin toxic effects (in 18 patients [16%]), asthenia (in 11 patients [9%]), stomatitis (in 7 patients [6%]), and febrile neutropenia (in 3 patients [3%]). CONCLUSIONS AND RELEVANCE: Although neither of the 2 arms met the primary end point, the findings indicate that a 4-month induction regimen of mFOLFOXIRI plus cetuximab is feasible and provides relevant activity results, leading to a high surgical resection rate. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02295930.
引用
- Cremolini C, Antoniotti C, Lonardi S, et al. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. JAMA Oncol. 2018. PMID: 29450468. doi:10.1001/jamaoncol.2017.5314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。